Abstract: A new concept in multifunctional anticancer agents is demonstrated. Tetrakis-(diisopropylguanidino) zinc phthalocyanine (Zn-DIGP) exhibits excellent properties as a photodynamic therapy (PDT) agent, as well as potential anti-metastatic activities in vivo. Zn-DIGP exhibits good cellular uptake and low toxicity in the dark (EC50 > 80 M) and is well tolerated upon its intravenous injection into mice at 8 mg/kg. Upon photoexcitation with red laser light (660 nm), Zn-DIGP exhibits a high quantum yield for singlet oxygen formation (Φ 0.51) that results in potent phototoxicity to cell cultures (EC50 0.16 M). Zn-DIGP is also capable of inhibiting the formation of tumor colonies in the lungs of C57BL/6 mice injected with B16F10 cells. Zn-DIGP therefore inhibits cancer growth by both lightdependent and light-independent pathways. The anti-metastatic activities of Zn-DIGP possibly result from its ability to interfere with the signaling between chemokine CXCL10 and the G protein-coupled receptor CXCR3. Zn-DIGP is a competitive inhibitor of CXCR3 activation (IC50 = 3.8 M) and selectively inhibits downstream events such as CXCL10-activated cell migration. Consistent with the presence of feedback regulation between CXCR3 binding and CXCL10 expression, Zn-DIGP causes overexpression of CXCL10. Interestingly, Zn-DIGP binds to CXCR3 without activating the receptor yet is able to cause endocytosis and degradation of this GPCR. To the best of our knowledge, Zn-DIGP is the first PDT agent that can facilitate the photodynamic treatment of primary tumors while simultaneously inhibiting the formation of metastatic tumor colonies by a light-independent mode of action. 
Skin cancers account for about half of all cancers in the United States, where complications associated with the spread of melanoma to vital organs are a leading cause of death for women aged 19 to 50 years. (1, 2) While surgery remains the main treatment option for advanced malignancies,(3) early-stage melanoma and non-melanoma skin cancers can be treated with photodynamic therapy (PDT).(4-6) Photodynamic therapy involves utilization of photosensitizers that exhibit phototoxicity by two common mechanisms, Type 1 involves longlived triplet states of the photosensitizer that react directly with cellular components; Type 2 involves formation of singlet oxygen which triggers cell death.(7) Many photosensitizing agents have been evaluated in the clinic, (8, 9) but only four PDT agents, all of which being porphyrin derivatives, are currently approved by the FDA: Verteporfin (Visudyne®), Porfimer Sodium (Photofrin®), 5-aminolevulinic acid (Luvulan®), and 5-aminolevulinic acid methyl ester (Visudyne®). None of these PDT agents, however, are ideal candidates for treating melanoma.
In clinical trials, poor results were obtained when porphyrin-based PDT agents were used to treat melanoma and related maladies. (10) One key limitation to these compounds is their relatively short maximal wavelengths of excitation (λ max ≈ 630 nm), where melanin-rich tissues absorb too much light energy to be useful.(4) In terms of tissue permeability, photosensitizers with longer wavelengths of excitation should provide better treatment options. (11) For example, the chlorinbased derivative e6 (λ max ≈ 660 nm) was successfully used to treat melanoma-derived skin metastases in human patients,(5) and a related compound "mono-L-aspartyl chlorin e6" exhibited good efficacy in a Phase II clinical trial. (12) Phthalocyanines (λ max ≈ 690 nm) exhibit absorbance into the near-infrared, (13) and can therefore utilize longer wavelengths of light than porphyrins and chlorins for better tissue permeability.
The photophysical properties of phthalocyanines are known to be strongly influenced by the centrally-coordinated metal ion. For example, copper-containing phthalocyanines are essentially photo-inert and used as tattoo inks; while aluminum, silicon, and zinc-containing phthalocyanines are highly phototoxic. (14) Zinc and silicon-containing phthalocyanines have exhibited promising PDT activities in pre-clinical and phase-I clinical trials for chroidal neovascularization and cutaneous neoplasms. (15, 16) However, the notorious insolubility and aggregation properties of phthalocyanines can negatively affect their cellular uptake and ability to act as photosensitizers. (17) Given these limitations, efforts have been directed towards the synthesis of water soluble and cell-permeable phthalocyanine derivatives. (18) For example, we recently synthesized a new family of cationic phthalocyanines termed "guanidino phthalocyanines" (GPcs) containing four guanidinium groups. (19) One such derivative, tetrakis-(diisopropyl-guanidine) zinc phthalocyanine "Zn-DIGP" exhibits good cellular uptake and the ability to modulate gene expression. Here we report that Zn-DIGP inhibits the formation of metastatic tumor colonies in the lung tissues of mice injected with B16F10 cells. Contrary to our expectations, this inhibition appears to proceed via a G-quadruplex independent mode of action. According to cell-based studies, the anti-metastatic activities of Zn-DIGP are probably a result of its ability to disrupt signaling between chemokine CXCL10 and its receptor CXCR3. (25) (26) (27) Zn-DIGP binds to CXCR3 and inhibits CXCL10-induced receptor activation with an IC 50 = 3.8 µM. Unlike previously reported CXCR3 antagonists, Zn-DIGP also exhibits potent phototoxicity as well as the ability to cause CXCR3 endocytosis and degradation. Taken together, these results suggest that Zn-DIGP and other GPcs may serve as multi-functional PDT agents, where light energy can be harnessed for the treatment of primary surface tumors while simultaneously inhibiting the formation of new tumor colonies by interfering with chemokine signaling.
RESULTS AND DISCUSSION

GPcs: Photophysical Properties and Phototoxicity
During our initial synthesis of guanidino phthalocyanines (GPcs), a new de-metallation reaction that furnished tetrakis-(diisopropyl-guanidine) phthalocyanine "DIGP" (1) for absorbance, excitation and emission spectra). We therefore measured the quantum yields for photon emission and singlet oxygen generation of 1 -5 in DMSO ( Table 1 ). The known zinc phthalocyanines "Zn-Pc" (6) and zinc phthalocyanine tetrasulfonate "Zn-PcS4" (7) were included as reference compounds. The quantum yield of Zn-DIGP for luminescence (Φ = 0.28) was more than 100-fold higher than the other metal-containing DIGPs (Table 1) . The bright emissions from Zn-DIGP facilitate its direct visualization in cells using fluorescence microscopy. The cytotoxic and phototoxic activities of Zn-DIGP were quantified using a standard Alamar Blue assay that reports the combined effects of proliferation and metabolism on total cellular respiration. B16F10 cells were treated with variable concentrations of 1 -7 for 24 hours and irradiated with a 660 nm laser (250 mW) for 90 seconds. Three hours later, resazurin was added and its metabolic conversion into resorufin was compared with untreated cells to determine EC 50 values (see Figure 3A for representative data). A comparison of EC 50 values for irradiated (+hν) versus non-irradiated samples (-hν) reveals the relative phototoxicity of each compound ( Table   1 ). The metal-free compound "DIGP" (1) shows no significant change in cytotoxicity upon irradiation (EC 50 ≈ 30 µM), whereas the metal-containing derivatives 2 -7 all exhibit minimal dark toxicity (EC 50 > 80 µM) and highly variable toxicity upon irradiation (EC 50 = 0.2 -80 µM, Table 1 ). Of all derivatives tested, Zn-DIGP exhibits the most potent phototoxicity, with more than a 400-fold decrease in EC 50 value (EC 50 = 0.16 µM) upon irradiation. According to these results, Zn-DIGP is approximately 20-times more phototoxic than the well-studied anionic phthalocyanine "Zn-PcS4" (7) . (29, 30) To determine the probable mechanism of Zn-DIGP's phototoxicity, the quantum yield of singlet oxygen was measured for compounds 1 -7 by monitoring the time-dependent photobleaching of 
Microarray, qRT-PCR, and ELISA for Mechanistic Lead Identification
To provide a relatively unbiased approach for identifying the probable mechanism(s) of Zn-DIGP's anti-metastatic activities, its impact on global gene expression was evaluated using that Zn-DIGP might mimic CXCL10 to competitively bind CXCR3. To test this hypothesis, competitive displacement experiments were conducted using immobilized CXCR3 receptors and 125 I-labeled CXCL10. As a control, unlabelled CXCL10 was titrated and the apparent K i (0.57 ± 0.02 nM) was found to be similar to previous reports. (45) Using this assay, Zn-DIGP was found to displace 125 I-labelled CXCL10 with an apparent K i of 29 ± 1 µM ( Figure 7A ).
To evaluate the functional impact of CXCR3 binding by Zn-DIGP, agonist assays were performed by monitoring changes in intracellular calcium levels in Chem 1 cells that overexpress CXCR3. As a control, unlabelled CXCL10 was titrated and the apparent EC 50 value measured for receptor activation (13 ± 1 nM) was similar to previous reports. (45) As shown in Figure 7B , the addition of Zn-DIGP did not cause any detectable increase in intracellular calcium levels, indicating the absence of CXCR3 activation.
To test the ability of Zn-DIGP to inhibit activation of CXCR3 by CXCL10, Zn-DIGP was incubated with Chem 1 cells for 15 min followed by the addition of 13 nM CXCL10. Reduced calcium levels were observed in Zn-DIGP-treated samples ( Figure 7C ). The IC 50 of Zn-DIGP for CXCL10-CXCR3 inhibition was 3.8 ± 0.6 µM. Surprisingly, the IC 50 for CXCR3 inhibition was To assess the ability of Zn-DIGP to selectively inhibit CXCR3 downstream signaling, we investigated CXCL10-activated cellular motility using scratch assays ( Figure 9 ). (25, 48, 49) As a selectivity control, the chemotactic cytokine CCL21 that binds to receptor CCR7 was included.(50) Both CXCL10 and CCL21 stimulate cell migration in the absence of Zn-DIGP ("untreated" samples, Figure 9B ). In the presence of 5 µM, the changes in migration indices reveal inhibition of CXCL10-mediated cellular migration, but not of CCL21-activated migration ( Figure 9 ). Similar results were also obtained using matrigel-based invasion assays (Supplementary Figure S7) . Interestingly, the same migration index was observed for cells treated with 5 µM of Zn-DIGP from 2 -100 nM of added CXCL10 ( Figure 9 ). Together these results are consistent with the ability of Zn-DIGP to selectively inhibit CXCL10-mediated signaling via CXCR3 binding and endocytosis. Experiments to characterize the anti-metastatic activities of Zn-DIGP and its potential mode of action were conducted using a concentration of 5 µM, where no changes in cellular respiration or proliferation were observed under conditions of ambient light. Given the extreme side effects of cytotoxic chemotherapies currently used for treating metastatic melanoma,(51) the ability of Zn-DIGP to interfere with metastasis formation without indiscriminant cell killing presents a highly attractive possibility. The CXCR3 antagonist "AMG487" was also reported to have little or no impact on cellular proliferation in serum-containing media. (25, 27) . Consistent with its low toxicity, AMG487 did not impact local tumor growth or survival in vivo, but it was able to inhibit metastasis. (25) In the case of Zn-DIGP, the site-specific destruction of the primary tumor can be achieved using laser light activation, while simultaneously inhibiting the formation of new metastases in vital organs by interfering with chemokine signaling.
CONCLUSIONS
Zn-DIGP is well-tolerated upon intravenous injection into C57BL/6 mice at 8 mg / kg, where it exhibits a light-independent mode of action by inhibiting the formation of pulmonary metastases. 
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